Relocalization evaluation of arbidol in the treatment of COVID-19

Yujiao Bai¹, Xianqing Zhang², Meng Yang¹, Lin Zhang³, and Xu Jia¹

April 16, 2024

Abstract

Background The spread of COVID-19 continues, the mutation of SARS-COV-2 is still difficult to control, and the need for antiviral drugs to treat COVID-19 remains urgent. The use of arbidol in the treatment of COVID-19 is limited and controversial. Methods To clarify the efficacy of arbidol on COVID-19, we collected 25 cases and 178 related studies. We analyzed the treatment information of arbidol based on the obtained cases, expanded the scope of the study, and collected current studies on the treatment of COVID-19 in various databases for in-depth analysis. Results History analysis showed that arbidol was effective (76% cure rate) compared with other drugs. However, compared with other antiviral drugs or standard therapy, the arbidol group had no significant advantage in reducing the time to negative virus transformation, length of hospital stays, or improvement in CT (MD=0.22, 95%CI -0.29-0.73; MD = 0.61, 95% CI 1.46 to 2.67; RR=1.15, 95%CI 0.88-1.50); Analysis of adverse events showed no significant difference between the arbidol group and the other groups (RR=0.82, 95%CI 0.25-2.71). Conclusion Our study showed that arbidol had no significant effect on COVID-19, but showed a slight advantage in CT improvement and adverse events. Our study objectively evaluated the efficacy of arbidol in the treatment of COVID-19 and provided some guidance for arbidol in the treatment of COVID-19.

Hosted file

manuscript.docx available at https://authorea.com/users/740500/articles/713366-relocalization-evaluation-of-arbidol-in-the-treatment-of-covid-19

Hosted file

Cover letter.docx available at https://authorea.com/users/740500/articles/713366-relocalization-evaluation-of-arbidol-in-the-treatment-of-covid-19

Hosted file

Figure Captions.docx available at https://authorea.com/users/740500/articles/713366-relocalization-evaluation-of-arbidol-in-the-treatment-of-covid-19


Hosted file


Tables.docx available at https://authorea.com/users/740500/articles/713366-relocalization-evaluation-of-arbidol-in-the-treatment-of-covid-19

¹Affiliation not available


²Chengdu Medical College


³Zhejiang University School of Medicine







In favor of null: $log_e(BF_{01}) = -1.24$, $r_{Cauchy}^{JZS} = 0.71$






In favor of null: $log_e(BF_{01}) = -0.98$, $r_{Cauchy}^{JZS} = 0.71$







| Experimental | Control | Mean Difference | Mea

